Pharma deal analysis divides US FTC
The US Federal Trade Commission has approved Bristol-Myers Squibb’s acquisition of Celgene on a party-line vote, but both Democratic commissioners called for the agency to look more broadly at consolidation in the pharmaceutical industry.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.